文献速递淋巴瘤

GAS1、IL-1RAP和PRF1在ALK阳性间变性大细胞淋巴瘤患者中的表达及临床意义

[Expressions and clinical significance of GAS1, IL-1RAP and PRF1 in patients with ALK positive anaplastic large cell lymphoma].
PubMed 文献 · Zhonghua Xue Ye Xue Za Zhi · 2018-01-01

Objective: To investigate the expressions of growth arrest-specific protein (GAS1), IL-1 receptor accessory protein (IL-1RAP) and perforin (PRF1) in patients with anaplastic lymphoma kinase positive, anaplastic large cell lymphoma (ALK+ ALCL) and their relationships with clinical…

要点

  • ALK阳性间变性大细胞淋巴瘤中GAS1、IL-1RAP、PRF1基因和蛋白表达均高于对照组。
  • LDH升高或IPI≥3分者GAS1表达降低,Ⅲ/Ⅳ期或IPI≥3分者PRF1表达降低。
  • GAS1或PRF1高表达者总生存和无进展生存期更长。

核心结论

  • GAS1、IL-1RAP、PRF1基因可作为ALK阳性间变性大细胞淋巴瘤的分子标志,有潜在诊断价值,可用于少数诊断困难病例的鉴别。
  • GAS1、PRF1基因高表达的ALK阳性间变性大细胞淋巴瘤患者疗效及预后更好。

研究设计与样本

  • 以2011年1月至2016年9月的26例ALK阳性间变性大细胞淋巴瘤患者为研究对象。
  • 以12例ALK阴性间变性大细胞淋巴瘤、13例外周T细胞淋巴瘤非特指型和8例血管免疫母细胞性T细胞淋巴瘤患者为对照。
  • 采用实时荧光定量PCR和免疫组化法检测病理组织标本中GAS1、IL-1RAP、PRF1基因和蛋白表达水平并结合临床资料分析。

主要发现

  • ALK阳性间变性大细胞淋巴瘤组GAS1、IL-1RAP、PRF1基因和蛋白表达水平均高于3个对照组(P值均<0.05),对照组组间差异无统计学意义(P<0.05)。
  • LDH升高者GAS1表达为0.77对1.38(z=-3.292,P=0.001),IPI≥3分者GAS1表达为0.62对1.29(z=-2.495,P=0.013),均降低。
  • Ⅲ/Ⅳ期者PRF1表达为0.89对1.18(z=-2.212,P=0.027),IPI≥3分者PRF1表达为0.48对1.13(z=-2.008,P=0.045),均降低。
  • 不同临床特征组间IL-1RAP基因表达水平差异均无统计学意义(P值均≥0.05)。
  • 以各基因表达中位数为分界点,GAS1、PRF1基因高表达组患者较低表达组有更长的总生存和无进展生存期(P值均<0.05)。

局限性

  • 原文未报告局限性

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Objective: To investigate the expressions of growth arrest-specific protein (GAS1), IL-1 receptor accessory protein (IL-1RAP) and perforin (PRF1) in patients with anaplastic lymphoma kinase positive, anaplastic large cell lymphoma (ALK+ ALCL) and their relationships with clinical significances and the prognoses of ALK+ ALCL. Methods: Twenty-six formalin-fixed paraffin-embedded (FFPE) samples of ALK+ ALCL patients who were diagnosed from January 2011 to September 2016 were collected. Twelve FFPE samples of patients with ALK+ALCL, 13 FFPE samples of patients with peripheral T cell lymphoma (not otherwise specified) (PTCL-NOS) and 8 FFPE samples of patients with angioimmunoblastic T-cell lymphoma (AITL) were used as control groups. RQ-PCR and immunohisto-chemical staining were used to detect the mRNA and protein expressions of GAS1, IL-1RAP and PRF1. The clinical data were analyzed. Results: ①The expression levels of GAS1, IL-1RAP and PRF1 gene and protein in ALK+ ALCL group were higher than those of the control groups (P<0.05), but the expression levels had no statistically significant differences between the control groups (P>0.05). ②Patients with elevated lactate dehydrogenase (LDH) (0.77 vs 1.38, z=-3.292, P=0.001) or International prognostic index (IPI)≥3(0.62 vs 1.29, z=-2.495, P=0.013) had lower expression level of GAS1. Patients with stage Ⅲ/Ⅳ disease (0.89 vs 1.18, z=-2.212, P=0.027) or IPI≥3 (0.48 vs 1.13, z=-2.008, P=0.045) had lower expression level of PRF1. IL-1RAP expression level was not associated with clinical features. ③ALK+ ALCL patients in complete remission (CR) group had higher expression levels of GAS1 and PRF1 than patients in non-remission (NR) group (P values were 0.016 and 0.009). ④Kaplan-Meier survival analysis showed that patients with high expression levels of GAS1 and PRF1 had longer median overall survival and progression-free survival than patients with low expression levels of GAS1 and PRF1. Conclusion: GAS1, IL-1RAP and PRF1 could be molecular markers for ALK+ ALCL patients. They have potential diagnostic value and can be used for differential diagnosis in some difficult cases. ALK+ ALCL patients with high expression levels of GAS1 or PRF1 have better curative effects and prognoses. 目的: 研究生长停滞特异性蛋白(GAS1)、IL-1受体辅助蛋白(IL-1RAP)、穿孔素(PRF1)在间变性淋巴瘤激酶阳性的间变性大细胞淋巴瘤(ALK+-ALCL)患者中的表达及其临床意义。 方法: 以2011年1月至2016年9月的26例ALK+ ALCL患者为研究对象,以12例ALK-ALCL、13例外周T细胞淋巴瘤非特指型和8例血管免疫母细胞性T细胞淋巴瘤患者为对照。收集所有患者的病理组织标本,采用实时荧光定量PCR和免疫组化法检测标本中GAS1、IL-1RAP、PRF1基因和蛋白表达水平,结合患者的临床资料对数据进行分析。 结果: ①26例ALK+ ALCL患者组织中,GAS1、IL-1RAP、PRF1基因和蛋白表达水平均高于3个对照组,差异有统计学意义(P值均<0.05),对照组组间基因与蛋白表达水平差异无统计学意义(P<0.05)。②存在LDH升高(0.77对1.38,z=-3.292,P=0.001)、国际预后指数(IPI)评分≥3分(0.62对1.29,z=-2.495,P=0.013)时,ALK+ ALCL患者的GAS1基因表达水平降低;疾病分期为Ⅲ/Ⅳ期(0.89对1.18,z=-2.212,P=0.027)、IPI评分≥3分(0.48对1.13,z=-2.008,P=0.045)时,ALK+ ALCL患者的PRF1基因表达水平降低;不同临床特征患者组间IL-1RAP基因表达水平差异均无统计学意义(P值均≥0.05)。③化疗后达完全缓解的ALK+ ALCL患者GAS1、PRF1基因表达水平差异均无统计学意义(P值分别为0.016、0.009)。④以ALK+ ALCL患者中各基因表达的中位数为分界点,GAS1、PRF1基因高表达组患者较低表达组有更长的总生存和无进展生存期(P值均<0.05)。 结论: GAS1、IL-1RAP、PRF1基因可作为ALK+ ALCL的分子标志,有潜在的诊断价值,可用于少数诊断困难病例的鉴别。GAS1、PRF1基因高表达的ALK+ ALCL患者疗效及预后更好。.

来源:Zhonghua Xue Ye Xue Za Zhi,查看原文。版权归原作者所有。

引用

  1. Jiang Y, Cao D, Xu CG, et al. [Expressions and clinical significance of GAS1, IL-1RAP and PRF1 in patients with ALK positive anaplastic large cell lymphoma]. Zhonghua Xue Ye Xue Za Zhi. 2018. PMID: 29562445. doi:10.3760/cma.j.issn.0253-2727.2018.02.008

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。